1 / 23

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Explore the future of endocrine combinations in postmenopausal patients with HR+ MBC. Review treatment challenges, algorithm for management, and study results such as PALOMA-3 and BELLE-2. Understand sequential ET use and ongoing clinical questions.

jeileen
Download Presentation

Endocrine Combinations in HR-Positive MBC: The Future Is Now

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Endocrine Combinations in HR-Positive MBC: The Future Is Now

  2. Program Overview

  3. Treatment Challenges in Postmenopausal Patients With HR+ Advanced Disease

  4. Algorithm for Management of Postmenopausal ER+ MBC

  5. Visceral Crisis

  6. Combined ET Results

  7. Sequential Use of ET for Advanced Breast Cancer

  8. Phase 2 FIRST Trial: Fulvestrant vs Anastrozole for Advanced Breast Cancer

  9. FALCON: Study Design

  10. PALOMA-1: Study Design

  11. PALOMA-1: PFS (ITT Population)

  12. PALOMA-1: All-Causality AEs Occurring in ≥10% of Patients (Safety Population)

  13. PALOMA-2: Study Design

  14. PALOMA-3: Study Design

  15. PALOMA-3 Results

  16. The PI3K Pathway in Breast Cancer

  17. BELLE-2: Buparlisib Plus Fulvestrant in Advanced HR+ Disease

  18. Monotherapy vs Combination Therapy

  19. Ongoing Clinical Questions

  20. Conclusions

  21. Abbreviations

  22. Abbreviations (cont)

More Related